Asthma |
· Prescribed inhaled (or oral) corticosteroids as
controller medication should be further applied to patients with asthma
as cessation may lead to asthma exacerbations. |
ARIA-EAACI statement on
Asthma and COVID-19.16
|
Allergic rhinitis
|
· Intranasal corticosteroids (including nasal sprays) can be
further applied in COVID-19 patients at the recommended dosages and a
cessation or interruption is not recommended.
· Furthermore, a cessation or interruption of allergen immunotherapy
(AIT) for both the subcutaneous route (SCIT) or sublingual route (SLIT)
is not recommended in asymptomatic patients without suspicion for
SARS-CoV-2 infection and/or contact to SARS-CoV-2 positive individuals
or in other conditions as outlined.
|
corticosteroids in allergic rhinitis in COVID-19 infected patients: An
ARIA-EAACI statement
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected
patients: An ARIA-EAACI statement.21
Handling of allergen immunotherapy in the COVID-19 pandemic: An
ARIA-EAACI statement. 22
|
Biological-Treatment
|
· Biologicals should be applied in type 2 inflammations (asthma,
atopic dermatitis, chronic rhinosinusitis with nasal polyps) via
self-application in non-infected patients
· In patient with an active SARS-CoV-2 infection treatment with
biologicals should be paused and re-initiated after recovery and
SARS-CoV-2 negativity of patients.
|
Considerations on biologicals for patients with allergic disease in
times of the COVID-19 pandemic: an EAACI Statement.
28
|
Children
|
· Less severe courses of COVID-19 in the pediatric population have
been reported.
· Similar to the adult age group, severe forms of asthma and
immunodeficiencies are reported to be risk factors.
· A sufficient control of symptoms in children with allergies,
asthma and immunodeficiency in accordance with current guidelines is key
in the current pandemic.
|
Managing childhood allergies and immunodeficiencies during respiratory
virus epidemics - The 2020 COVID-19 pandemic: A statement from the
EAACI-section on pediatrics.25
|
Drug allergy
|
· Drugs being used in different phases of COVID-19 disease seem to
cause rare but potentially severe drug hypersensitivity reactions
(DHRs).
· Most of these DHRs affect the skin and are non-immediate.
· The most important differential diagnosis of these DHRs is
COVID-19 related exanthems.
|
Diagnosis and management of the drug hypersensitivity reactions in
coronavirus disease drug hypersensitivity.27
|
Ocular allergy
|
· An international survey revealed that experts in the field
recommend that during the ongoing pandemic therapy strategies in line
with current guidelines should be followed.
· However, particular caution for the use of corticosteroids and
immunomodulators in COVID-19 infected patients is expressed.
|
Managing ocular allergy in the time of COVID-19.
19
|
Organization of an allergy clinic
|
· Recommendations on operational plans and procedures to maintain
high standards in the daily clinical care of allergic patients whilst
ensuring necessary safety in the current COVID-19 pandemic should be
followed.
· Nine different scenarios and topics are discussed.
|
COVID-19 pandemic: Practical considerations on the organization of an
allergy clinic - an EAACI/ARIA Position Paper.
23
|